Nolvadex (Tamoxifen Citrate)

Tamoxifen citrate acts as a selective estrogen receptor modulator. It binds to estrogen receptors in breast tissue, blocking estrogen‑driven cell growth, while partially stimulating receptors in bone and the uterus. This selective antagonism and agonism disrupts estrogen signaling pathways that fuel certain tumors.

The dosing regimen for tamoxifen citrate is individualized. A qualified prescriber determines the appropriate dose, frequency, and duration based on the specific indication, patient characteristics, and clinical guidelines. Patients should follow the prescribing information provided by their healthcare professional.

Tamoxifen citrate is contraindicated in pregnancy because it may cause fetal harm. Women of child‑bearing potential should use effective contraception during treatment and for a period after discontinuation. Limited data exist for breastfeeding, and the drug is generally not recommended while nursing.

To order Nolvadex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nolvadex (tamoxifen) is a well‑established selective estrogen receptor modulator, whereas alternatives such as aromatase inhibitors lower estrogen production rather than block its receptor. Tamoxifen is often chosen for pre‑menopausal patients and for risk‑reduction strategies, while aromatase inhibitors are preferred in post‑menopausal settings.

Nolvadex should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, excessive heat and direct light to maintain potency throughout the shelf life.

Nolvadex is administered orally as a tablet. Patients swallow the tablet whole with water, typically once daily, unless the prescribing clinician advises a different schedule. Consistency with food intake is not required, but patients should follow the specific instructions given by their healthcare provider.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, endometrial cancer due to partial agonist activity in uterine tissue, and severe allergic reactions. Patients should be monitored regularly for signs of clotting, abnormal uterine bleeding, or hypersensitivity.

Nolvadex is contraindicated in individuals with known hypersensitivity to tamoxifen or any of its excipients, in pregnant women, and in patients with a history of thromboembolic disorders unless the benefits outweigh the risks. Clinicians should also exercise caution in patients with active liver disease or uncontrolled uterine pathology.